Methods for treating rheumatoid arthritis using human...

Details Methods for treating rheumatoid arthritis using human... Methods for treating rheumatoid arthritis using human...

2007-04-17

2009-06-02

Saunders, David A (Department: 1644)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Monoclonal antibody or fragment thereof

C424S145100, C424S158100, C424S810000, C514S249000

Reexamination Certificate

active

07541031

ABSTRACT:
Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., Kd=10−8M or less), a slow off rate for hTNFα dissociation (e.g., Koff=10−3sec−1or less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFα and for inhibiting hTNFα activity, e.g., in a human subject suffering from a disorder in which hTNFα activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.

REFERENCES:
patent: 5231024 (1993-07-01), Moeller et al.
patent: 5654407 (1997-08-01), Boyle et al.
patent: 5795967 (1998-08-01), Aggarwal et al.
patent: 5859205 (1999-01-01), Adair et al.
patent: 5877293 (1999-03-01), Adair et al.
patent: 5929212 (1999-07-01), Jolliffe et al.
patent: 5994510 (1999-11-01), Adair et al.
patent: 6090382 (2000-07-01), Salfeld et al.
patent: 6258562 (2001-07-01), Salfeld et al.
patent: 6270766 (2001-08-01), Feldman et al.
patent: 6448380 (2002-09-01), Rathjen et al.
patent: 6451983 (2002-09-01), Rathjen et al.
patent: 6498237 (2002-12-01), Rathjen et al.
patent: 6509015 (2003-01-01), Salfeld et al.
patent: 6593458 (2003-07-01), Rathjen et al.
patent: 7070775 (2006-07-01), Le et al.
patent: 7223394 (2007-05-01), Salfeld et al.
patent: 7250165 (2007-07-01), Heavner et al.
patent: 7276239 (2007-10-01), Le et al.
patent: 2003/0012786 (2003-01-01), Teoh et al.
patent: 2003/0049725 (2003-03-01), Heavner et al.
patent: 2003/0161828 (2003-08-01), Abdelghany et al.
patent: 2003/0206898 (2003-11-01), Fischkoff et al.
patent: 2003/0219438 (2003-11-01), Salfeld et al.
patent: 2003/0235585 (2003-12-01), Fischkoff et al.
patent: 2004/0009172 (2004-01-01), Fischkoff et al.
patent: 2004/0033228 (2004-02-01), Krause et al.
patent: 2004/0120952 (2004-06-01), Knight et al.
patent: 2004/0126372 (2004-07-01), Banerjee et al.
patent: 2004/0131614 (2004-07-01), Banerjee et al.
patent: 2004/0136989 (2004-07-01), Banerjee et al.
patent: 2004/0136990 (2004-07-01), Banerjee et al.
patent: 2004/0136991 (2004-07-01), Banerjee et al.
patent: 2004/0151722 (2004-08-01), Banerjee et al.
patent: 2004/0166111 (2004-08-01), Kaymakcalan et al.
patent: 2004/0219142 (2004-11-01), Banerjee et al.
patent: 2005/0123541 (2005-06-01), Heavner et al.
patent: 2005/0249735 (2005-11-01), Le et al.
patent: 2006/0009385 (2006-01-01), Hoffman et al.
patent: 2006/0018907 (2006-01-01), Le et al.
patent: 2006/0024293 (2006-02-01), Salfeld et al.
patent: 2006/0083741 (2006-04-01), Hoffman et al.
patent: 2006/0153846 (2006-07-01), Krause et al.
patent: 2006/0246073 (2006-11-01), Knight et al.
patent: 2007/0003548 (2007-01-01), Heavner et al.
patent: 2007/0041905 (2007-02-01), Hoffman et al.
patent: 2007/0071747 (2007-03-01), Hoffman et al.
patent: 2007/0081996 (2007-04-01), Hoffman et al.
patent: 2007/0172897 (2007-07-01), Maksymowych et al.
patent: 2007/0202104 (2007-08-01), Banerjee et al.
patent: 2007/0292442 (2007-12-01), Wan et al.
patent: 2007/0298040 (2007-12-01), Le et al.
patent: 2008/0025976 (2008-01-01), Le et al.
patent: 2008/0118496 (2008-05-01), Medich et al.
patent: 2008/0131374 (2008-06-01), Medich et al.
patent: 2008/0193466 (2008-08-01), Banerjee et al.
patent: 2008/0227136 (2008-09-01), Pla et al.
patent: 2008/0311043 (2008-12-01), Hoffman et al.
patent: 2009/0017472 (2009-01-01), Stuhlmuller et al.
patent: 186833 (1992-08-01), None
patent: 366043 (1994-03-01), None
patent: 212489 (1994-11-01), None
patent: 101681 (1994-12-01), None
patent: 659766 (1995-06-01), None
patent: 351789 (1998-11-01), None
patent: 492448 (2000-03-01), None
patent: 614984 (2001-08-01), None
patent: 2279077 (1994-12-01), None
patent: WO-91/02078 (1991-02-01), None
patent: WO-92/11383 (1992-07-01), None
patent: WO-92/16553 (1992-10-01), None
patent: WO-93/06213 (1993-04-01), None
patent: WO-94/29347 (1994-12-01), None
patent: WO-95/23813 (1995-09-01), None
Rader et al, Proc. Natl. Acad. Sci. USA, vol. 95, 8910-8915, 1998.
Rudikoff et al, Proc. Natl. Acad. Sci. USA, vol. 79, 1979-1983, 1982.
Abraham, Edward, et al., “Efficacy and Safety of Monoclonal Antibody to Human Tumor Necrosis Factor α in Patients with Sepsis Syndrome,”JAMA, vol. 273(12):934-941 (1995).
Barbuto, J.A.M. et al. “Production of Neutralizing Antibodies to Tumor Necrosis Factor by Human Tumor-Infiltrating B Lymphocytes”Proc. Am. Assoc. Cancer Res. 34:487, Abstract No. 2904 (Mar. 1993).
Bendtzen, K. et al. “Auto-antibodies to IL-1α and TNFα in Normal Individuals and in Infectious and Immunoinflammatory Disorders” inThe Physiological and Pathological Effects of Cytokines(Wiley-Liss, Inc., 1990) 447-52.
Boekstegers, P., et al., “Repeated administration of a F(ab′)2 fragment of an anti-tumor recrosis factor alpha monoclonal antibody in patients with severe sepsis: effects on the cardiovascular system and cytokine levels,”Shock, vol. 1(4):237-245 (1994).
Boyle, P. et al. “A Novel Monoclonal Human IgM Autoantibody which Binds Recombinant Human and Mouse Tumor Necrosis Factor- α”Cell. Immunol. 152:556-68 (1993).
Boyle, P. et al. “The B5 Monoclonal Human Autoantibody Binds to Cell Surface TNFα on Human Lymphoid Cells and Cell Lines and Appears to Recognize a Novel Epitope”Cell. Immunol. 152:569-81 (1993).
Brekke, Ole Henrik, et al., “Therapeutic antibodies for human diseases at the dawn of the twenty-first century,”Nature Reviews/Drug Discovery, vol. 2:52-62 (2003).
Chow, A.W. et al. “Effect of monoclonal antibody on human tumor necrosis factor (TNF MAb) on TNFα, IL-1β, and IL-6 levels in patients with sepsis syndrome”Clinical Research42:2 299A (1994).
Cohen, Jonathan, et al., “Intersept: An international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-α in patients with sepsis,”Crit Care Med, vol. 24(9):1431-1440 (1996).
Cox, J.P.L. et al. “A directory of human germ-line Vκsegments reveals a strong bias in their usage”Eur. J. Immunol. 24(2);827-36 (1994).
Department of Surgery, University of Toronto Annual Report, Jul. 1, 1998-Jun. 30, 1999—found online at http://www.surg.med.utoronto.ca/AnnRep/AR98—99/index.html.
Elliot, M.J. et al. “Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α” Arthritis & Rheumatism 36(12):1681-90 (1993).
Feldman, Marc, et al., “Anti-TNF∝ Therapy of Rheumatoid Arthritis: What Have We Learned?” Annu. Rev. Immunol., vol. 19:163-196 (2001).
Figini, Mariangela, et al., “In Vitro Assembly of Repertoires of Antibody Chains on the Surface of Phage by Renaturation,” J. Mol. Biol., vol. 239:68-78 (1994).
Fomsguaard, A. et al. “Auto-antibodies to Tumor Necrosis Factor α in Healthy Humans and Patients with Inflammatory Diseases and Gram-Negative Bacterial Infections” Scand. J. Immunol. 30:219-23 (1989).
Griffiths, A.D. et al. “Human anti-self antibodies with high specificity from phage display libraries” The EMBO J. 12(2):725-34 (1993).
Hawkins, Robert E., et al., “Selection of Phage Antibodies by Binding Affinity Mimicking Affinity Maturation,” J. Mol. Biol., vol. 226:889-896 (1992).
Holler, E., et al., “Modulation of acute graft-versus-host-disease after allogeneic bone marrow transplantation by tumor necrosis factor alpha (TNF alpha) release in the course of pretransplant conditioning: role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNF alpha (MAK 195F),” Blood,

Affiliated with

Also associated with

Rating

Methods for treating rheumatoid arthritis using human... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods for treating rheumatoid arthritis using human..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating rheumatoid arthritis using human... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4143407